Currax Pharmaceuticals LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Currax Pharmaceuticals LLC
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, research and development partnerships and commercial collaborations. This edition covers industry pacts that were signed in September and October 2019.
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
Teva has seen two US patents protecting the Contrave combination of naltrexone and bupropion ruled invalid on appeal. But it is no nearer bringing a generic of the weight-loss drug to market, as the Court of appeals upheld a later-expiring patent, albeit on a split decision.
With its WPLS-IV fund now fully committed, Wellington Partners has returned to the market and raised €210m in its WPLS-V fund which will focus on European biotech and medtech opportunities.
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Cypress Pharmaceutical, Inc.
- Hawthorn Pharmaceuticals, Inc.
- Nalpropion Pharmaceuticals, Inc.
- Pernix Therapeutics Holdings, Inc.
- Somaxon Pharmaceuticals, Inc.